Robert Lim

6.4k total citations · 1 hit paper
56 papers, 4.5k citations indexed

About

Robert Lim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Robert Lim has authored 56 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 14 papers in Molecular Biology. Recurrent topics in Robert Lim's work include Colorectal Cancer Treatments and Studies (23 papers), Genetic factors in colorectal cancer (8 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). Robert Lim is often cited by papers focused on Colorectal Cancer Treatments and Studies (23 papers), Genetic factors in colorectal cancer (8 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). Robert Lim collaborates with scholars based in Singapore, Canada and China. Robert Lim's co-authors include Arié Figer, Robert A. Wolff, Daniel de Castro, David Walde, John Hamm, Wendy R. Parulekar, H. Au, P. Murawa, Malcolm J. Moore and David Goldstein and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Robert Lim

54 papers receiving 4.4k citations

Hit Papers

Erlotinib Plus Gemcitabin... 2007 2026 2013 2019 2007 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
    2007 2.9k citations Malcolm J. Moore, David Goldstein et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Robert Lim 3.1k 1.4k 1.3k 1.1k 602 56 4.5k
Ulrik Lassen 2.2k 0.7× 1.6k 1.1× 1.7k 1.3× 1.0k 0.9× 527 0.9× 253 4.9k
Marc R. Theoret 4.5k 1.5× 1.2k 0.8× 1.4k 1.0× 824 0.8× 295 0.5× 139 6.8k
Peter Langmuir 1.8k 0.6× 1.6k 1.2× 1.3k 1.0× 507 0.5× 438 0.7× 56 4.7k
Kirsten B. Goldberg 2.7k 0.9× 1.3k 0.9× 979 0.7× 711 0.7× 211 0.4× 66 4.5k
Miao‐Zhen Qiu 2.5k 0.8× 1.6k 1.1× 1.6k 1.2× 1.3k 1.2× 380 0.6× 165 4.9k
Neeltje Steeghs 2.8k 0.9× 1.9k 1.4× 1.7k 1.3× 857 0.8× 291 0.5× 242 5.4k
Jimmy J. Hwang 2.5k 0.8× 814 0.6× 940 0.7× 637 0.6× 355 0.6× 159 4.2k
Roberto Iacovelli 2.1k 0.7× 2.6k 1.9× 1.5k 1.1× 1.2k 1.2× 248 0.4× 224 4.6k
Patrick M. Forde 4.0k 1.3× 2.7k 2.0× 934 0.7× 645 0.6× 301 0.5× 186 5.7k
Mark Kozloff 3.2k 1.0× 1.7k 1.2× 1.3k 1.0× 702 0.7× 218 0.4× 125 4.7k

Countries citing papers authored by Robert Lim

Since Specialization
Citations

This map shows the geographic impact of Robert Lim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Lim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Lim more than expected).

Fields of papers citing papers by Robert Lim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Lim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Lim. The network helps show where Robert Lim may publish in the future.

Co-authorship network of co-authors of Robert Lim

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Lim. A scholar is included among the top collaborators of Robert Lim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Lim. Robert Lim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tang, Nicole K. Y., Benjamin Koh, Robert Lim, et al.. (2025). Meta‐Analysis: Utilisation of Hepatocellular Carcinoma Surveillance. Alimentary Pharmacology & Therapeutics. 63(1). 8–16. 1 indexed citations
2.
Ho, George, Robert Lim, Leonard L.L. Yeo, et al.. (2025). Waitlist and Post‐Transplant Outcomes in Liver Transplantation for Alcohol‐Associated Liver Disease: An Individual Patient Data Meta‐Analysis. Alimentary Pharmacology & Therapeutics. 63(3). 330–340. 1 indexed citations
3.
Schieda, Nicola, Robert Lim, Matthew D. F. McInnes, et al.. (2018). Characterization of small (<4 cm) solid renal masses by computed tomography and magnetic resonance imaging: Current evidence and further development. Diagnostic and Interventional Imaging. 99(7-8). 443–455. 48 indexed citations
4.
Lim, Robert, et al.. (2018). Are growth patterns on MRI in small (< 4 cm) solid renal masses useful for predicting benign histology?. European Radiology. 28(8). 3115–3124. 13 indexed citations
5.
Lim, Robert, et al.. (2017). Multidisciplinary Retroperitoneal and Pelvic Soft-Tissue Sarcoma Case Conferences: The Added Value that Radiologists Can Provide. Current Oncology. 24(3). 171–175. 1 indexed citations
6.
Lim, Robert, Trevor A. Flood, Matthew D. F. McInnes, Luke T. Lavallée, & Nicola Schieda. (2017). Renal angiomyolipoma without visible fat: Can we make the diagnosis using CT and MRI?. European Radiology. 28(2). 542–553. 54 indexed citations
7.
8.
Cheng, Ann‐Lii, Gerardo Cornelio, Lin Shen, et al.. (2013). First-Line Cetuximab with Folfox or Folfiri Every 2 Weeks in Kras Wild-Type Metastatic Colorectal Cancer: Phase II Apec Study. Annals of Oncology. 24. iv34–iv35. 4 indexed citations
9.
Lim, Robert. (2011). Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: The ELSIE study. World Journal of Gastroenterology. 17(14). 1879–1879. 18 indexed citations
10.
Rajaratnam, R., C. Mann, P. Balasubramaniam, et al.. (2010). Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre. Clinical and Experimental Dermatology. 35(8). 853–862. 66 indexed citations
11.
Rajaratnam, Ratna, et al.. (2009). A retrospective analysis of 34 patients with cutaneous sarcoidosis assessed in a dermatology department. Clinical and Experimental Dermatology. 35(2). 131–134. 25 indexed citations
12.
Chowbay, Balram, Brian C. Goh, Srinivasa Rao Jada, et al.. (2008). Influence of UGT1A9 intronic I399C4T polymorphism on SN-38 glucuronidation in Asian cancer patients. Faculty of Health; Institute of Health and Biomedical Innovation. 2 indexed citations
13.
Wong, Alvin, et al.. (2008). Debulking nephrectomy followed by a “watch and wait” approach in metastatic renal cell carcinoma. Urologic Oncology Seminars and Original Investigations. 27(2). 149–154. 18 indexed citations
14.
Moore, Malcolm J., David Goldstein, John Hamm, et al.. (2007). Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. 25(15). 1960–1966. 2909 indexed citations breakdown →
15.
Sandanaraj, Edwin, Xiao Shu, Robert Lim, et al.. (2007). Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients. The Pharmacogenomics Journal. 8(3). 174–185. 28 indexed citations
16.
Yeo, Winnie, Michael Boyer, Hyun Cheol Chung, et al.. (2006). Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). Cancer Chemotherapy and Pharmacology. 59(3). 295–300. 14 indexed citations
17.
Xiang, Xiaoqiang, Srinivasa Rao Jada, Lu Fan, et al.. (2006). Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenetics and Genomics. 16(9). 683–691. 66 indexed citations
18.
Lim, Robert, et al.. (2005). Clinical and molecular characteristics of hereditary non‐polyposis colorectal cancer families in Southeast Asia. Clinical Genetics. 68(2). 137–145. 32 indexed citations
19.
20.
Guo, Jiayi, Robert Lim, Ross A. Soo, Adrian Leong, & Soo Chin Lee. (2004). APC I1307K and the E1317Q variants are not present in Chinese colorectal cancer patients. Genetics in Medicine. 6(4). 237–238. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ulrik Lassen Breakdown of academic impact, for papers by Marc R. Theoret Breakdown of academic impact, for papers by Peter Langmuir Breakdown of academic impact, for papers by Kirsten B. Goldberg Breakdown of academic impact, for papers by Miao‐Zhen Qiu Breakdown of academic impact, for papers by Neeltje Steeghs Breakdown of academic impact, for papers by Jimmy J. Hwang Breakdown of academic impact, for papers by Roberto Iacovelli Breakdown of academic impact, for papers by Patrick M. Forde Breakdown of academic impact, for papers by Mark Kozloff
Rankless by CCL
2026